This Biotech Company's Lead Candidate Treats Rare Cancers As Well As Covid-19

Dr. Trieu, CEO of Oncotelic Therapeutics OTLC, was recently a guest on Benzinga's All Access.

Oncotelic seeks to improve the outcomes and survival of cancer patients, with a special emphasis on rare pediatric cancers. Its lead asset, OT-101, has a rare pediatric designation for diffuse intrinsic pontine glioma. The company has a host of IPs that are being studied in indications as diverse as leukemia, Parkinson’s Disease and erectile dysfunction.

Mr. Trieu spoke about the nanomedicine platform his company is currently building out.

Watch the full interview here:

Featured photo by Marcelo Leal on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.